Eliem Therapeutics Inc (ELYM)
8.81
+0.12
(+1.38%)
USD |
NASDAQ |
Jun 14, 16:00
8.91
+0.10
(+1.14%)
After-Hours: 20:00
Eliem Therapeutics Net Income (Annual): -35.12M for Dec. 31, 2023
Net Income (Annual) Chart
Historical Net Income (Annual) Data
Date | Value |
---|---|
December 31, 2023 | -35.12M |
December 31, 2022 | -45.24M |
December 31, 2021 | -47.48M |
Date | Value |
---|---|
December 31, 2020 | -20.67M |
December 31, 2019 | -6.547M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Annual) Range, Past 5 Years
-47.48M
Minimum
2021
-6.547M
Maximum
2019
-31.01M
Average
-35.12M
Median
2023
Net Income (Annual) Benchmarks
Candel Therapeutics Inc | -37.94M |
Cyclacel Pharmaceuticals Inc | -22.56M |
Lipocine Inc | -16.35M |
GlycoMimetics Inc | -36.90M |
Lyell Immunopharma Inc | -234.63M |